The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Arancha Prada-Villaverde, Jesus Esquivel, Andrew M. Lowy, Maurie Markman, Terence Chua, Joerg Pelz, Dario Baratti, Joel M. Baumgartner, Richard Berri, Pedro Bretcha-Boix, Marcello Deraco, Guillermo Flores-Ayala, Olivier Glehen, Alberto Gomez-Portilla, Santiago González-Moreno, Martin Goodman, Evgenia Halkia, Shigeki Kusamura, Mecker Moller, Guillaume Passot & 8 others Marc Pocard, George Salti, Armando Sardi, Maheswari Senthil, John Spiliotis, Juan Torres-Melero, Kiran Turaga, Richard Trout

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.

METHODS: The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).

RESULTS: Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427).

CONCLUSION: These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.

Original languageEnglish
Pages (from-to)779-785
Number of pages7
JournalJournal of Surgical Oncology
Volume110
Issue number7
DOIs
StatePublished - Dec 1 2014

Fingerprint

oxaliplatin
Peritoneal Diseases
Mitomycin
Colonic Neoplasms
Drug Therapy
Neoplasms
Colorectal Neoplasms
Carcinoma
Survival Rate
Survival

Keywords

  • colorectal cancer with peritoneal carcinomatosis
  • cytoreductive surgery
  • hyperthermic intraperitoneal chemotherapy (HIPEC)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. / Prada-Villaverde, Arancha; Esquivel, Jesus; Lowy, Andrew M.; Markman, Maurie; Chua, Terence; Pelz, Joerg; Baratti, Dario; Baumgartner, Joel M.; Berri, Richard; Bretcha-Boix, Pedro; Deraco, Marcello; Flores-Ayala, Guillermo; Glehen, Olivier; Gomez-Portilla, Alberto; González-Moreno, Santiago; Goodman, Martin; Halkia, Evgenia; Kusamura, Shigeki; Moller, Mecker; Passot, Guillaume; Pocard, Marc; Salti, George; Sardi, Armando; Senthil, Maheswari; Spiliotis, John; Torres-Melero, Juan; Turaga, Kiran; Trout, Richard.

In: Journal of Surgical Oncology, Vol. 110, No. 7, 01.12.2014, p. 779-785.

Research output: Contribution to journalArticle

Prada-Villaverde, A, Esquivel, J, Lowy, AM, Markman, M, Chua, T, Pelz, J, Baratti, D, Baumgartner, JM, Berri, R, Bretcha-Boix, P, Deraco, M, Flores-Ayala, G, Glehen, O, Gomez-Portilla, A, González-Moreno, S, Goodman, M, Halkia, E, Kusamura, S, Moller, M, Passot, G, Pocard, M, Salti, G, Sardi, A, Senthil, M, Spiliotis, J, Torres-Melero, J, Turaga, K & Trout, R 2014, 'The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery', Journal of Surgical Oncology, vol. 110, no. 7, pp. 779-785. https://doi.org/10.1002/jso.23728
Prada-Villaverde, Arancha ; Esquivel, Jesus ; Lowy, Andrew M. ; Markman, Maurie ; Chua, Terence ; Pelz, Joerg ; Baratti, Dario ; Baumgartner, Joel M. ; Berri, Richard ; Bretcha-Boix, Pedro ; Deraco, Marcello ; Flores-Ayala, Guillermo ; Glehen, Olivier ; Gomez-Portilla, Alberto ; González-Moreno, Santiago ; Goodman, Martin ; Halkia, Evgenia ; Kusamura, Shigeki ; Moller, Mecker ; Passot, Guillaume ; Pocard, Marc ; Salti, George ; Sardi, Armando ; Senthil, Maheswari ; Spiliotis, John ; Torres-Melero, Juan ; Turaga, Kiran ; Trout, Richard. / The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. In: Journal of Surgical Oncology. 2014 ; Vol. 110, No. 7. pp. 779-785.
@article{6c78a75be58f4ff6998e43684d6b02c6,
title = "The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery",
abstract = "BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.METHODS: The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).RESULTS: Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427).CONCLUSION: These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.",
keywords = "colorectal cancer with peritoneal carcinomatosis, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC)",
author = "Arancha Prada-Villaverde and Jesus Esquivel and Lowy, {Andrew M.} and Maurie Markman and Terence Chua and Joerg Pelz and Dario Baratti and Baumgartner, {Joel M.} and Richard Berri and Pedro Bretcha-Boix and Marcello Deraco and Guillermo Flores-Ayala and Olivier Glehen and Alberto Gomez-Portilla and Santiago Gonz{\'a}lez-Moreno and Martin Goodman and Evgenia Halkia and Shigeki Kusamura and Mecker Moller and Guillaume Passot and Marc Pocard and George Salti and Armando Sardi and Maheswari Senthil and John Spiliotis and Juan Torres-Melero and Kiran Turaga and Richard Trout",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/jso.23728",
language = "English",
volume = "110",
pages = "779--785",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

AU - Prada-Villaverde, Arancha

AU - Esquivel, Jesus

AU - Lowy, Andrew M.

AU - Markman, Maurie

AU - Chua, Terence

AU - Pelz, Joerg

AU - Baratti, Dario

AU - Baumgartner, Joel M.

AU - Berri, Richard

AU - Bretcha-Boix, Pedro

AU - Deraco, Marcello

AU - Flores-Ayala, Guillermo

AU - Glehen, Olivier

AU - Gomez-Portilla, Alberto

AU - González-Moreno, Santiago

AU - Goodman, Martin

AU - Halkia, Evgenia

AU - Kusamura, Shigeki

AU - Moller, Mecker

AU - Passot, Guillaume

AU - Pocard, Marc

AU - Salti, George

AU - Sardi, Armando

AU - Senthil, Maheswari

AU - Spiliotis, John

AU - Torres-Melero, Juan

AU - Turaga, Kiran

AU - Trout, Richard

PY - 2014/12/1

Y1 - 2014/12/1

N2 - BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.METHODS: The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).RESULTS: Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427).CONCLUSION: These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.

AB - BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.METHODS: The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).RESULTS: Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427).CONCLUSION: These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.

KW - colorectal cancer with peritoneal carcinomatosis

KW - cytoreductive surgery

KW - hyperthermic intraperitoneal chemotherapy (HIPEC)

UR - http://www.scopus.com/inward/record.url?scp=84922329818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922329818&partnerID=8YFLogxK

U2 - 10.1002/jso.23728

DO - 10.1002/jso.23728

M3 - Article

VL - 110

SP - 779

EP - 785

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -